Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Howard Weintraub, MD

Clinical Director
NYU Medical Center
Member of the Healthcare Council

Howard Weintraub, MD, FACC, is the Clinical Director of Center for the Prevention of Cardiovascular Disease at NYU Medical Center. He has been a consultant for several organizations and has been a Cardiologist for the National Football League. Dr. Weintraub has written textbook chapters on evaluation and treatment of patients prior to noncardiac surgery. He has also authored several articles on endothelial function and participated in clinical trials for treatment of lipid disorders. Dr. Weintraub has been named to the editorial board of Cardiology Review. He is one of the senior faculty in Vascular Biology Working Group and the Coalition for the Advancement of Cardiovascular Health, and is also a consultant to several pharmaceutical companies. (This is me - Update Profile)


Employment History
2004 - present Clinical Director
NYU Medical Center

GLG Study Groups with Howard Weintraub, MD(?)

View All Study Groups with Howard Weintraub, MD

GLG NewsSM Analyses by Howard Weintraub, MD(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Another piece of good news for a very good drug | 11-08-2007
Analysis of: Ranexa(R) Significantly Reduces Incidence Of CV Death, MI Or Recurrent Ischemia In MERLIN TIMI-36 Patients With Elevated BNP | www.medicalnewstoday.com
Author: Howard Weintraub, MD, Clinical Director, NYU Medical Center

By restoring function in the late Na channel and hence improving diastolic function (amongst other things), Ranexa has worked terrifically in my patients with any evidence for diastolic dysfunction. This typically manifests with shortness of breath and can be associated with an elevated level...

Even more benefit. | 11-08-2007
Analysis of: Ranexa(R) Significantly Reduces Incidence Of CV Death, MI Or Recurrent Ischemia In MERLIN TIMI-36 Patients With Elevated BNP | www.medicalnewstoday.com
Author: Howard Weintraub, MD, Clinical Director, NYU Medical Center

The good news gets better as there is now data from MERLIN that corroborates the news from CARISA showing a reduction in HbGA1C that was significant.

This one may hurt. | 06-15-2007
Analysis of: FDA Advisory Committee Did Not Recommend Approval Of Rimonabant (ZIMULTI(R)) For Use In Obese And Overweight Patients With Associated Risks Factors | www.medicalnewstoday.com
Author: Howard Weintraub, MD, Clinical Director, NYU Medical Center

It is clear that the panel felt that there was inadequate data on the psychiatric implications of rimonabant. It is a strong statement coming in the wake of the rosiglitazone mess (with strong recollections of cerivastatin and Vioxx) demonstrating that the FDA will be very finicky about approvals in...

This one may hurt. | 06-15-2007
Analysis of: FDA Advisory Committee Did Not Recommend Approval Of Rimonabant (ZIMULTI(R)) For Use In Obese And Overweight Patients With Associated Risks Factors | www.medicalnewstoday.com
Author: Howard Weintraub, MD, Clinical Director, NYU Medical Center

It is clear that the advisory panel is more concerned with safety in a limited population that the broader impact of obesity and its metabolic problems and acceleration of diabetes and atherosclerosis. This demonstrates the likelihood that the FDA will likely be posturing to reflect the rosiglitazone...

GLG InstituteSM Seminars with Howard Weintraub, MD(?)

 
Howard Weintraub, MD has not participated in any GLGi Seminars.
View all GLG InstituteSM Seminars in Healthcare

Request a project with Howard Weintraub, MD









Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-09-05T01:45:16.907